Online inquiry

IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5463MR)

This product GTTS-WQ5463MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets tcdB gene. The antibody can be applied in Clostridium difficile infectious diarrhea research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_003434531.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57299394
UniProt ID P18177
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5463MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8046MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ15985MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ15302MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ10317MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ5865MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ11586MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ13962MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ14082MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-421
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW